RLMD
Relmada Therapeutics, Inc.Healthcare · $393M market cap
Verdict
We can't put a fair value on RLMD right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow RLMD
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 9, 2026: 4 open-market purchases worth $1.7M. Why purchases matter
Purchases
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works